BioCentury
ARTICLE | Finance

Versant seizes the RNA moment

Why Versant seeded and launched RNA epigenetics play Gotham with $54M

October 12, 2018 9:45 PM UTC

As the RNA space continues to heat up, Versant Ventures opted out of companies looking to modify RNA directly, and instead seeded and launched RNA epigenetics company Gotham Therapeutics.

Versant co-led Gotham’s $54 million series A round, announced on Oct. 10, with Forbion Capital Partners and SR One. Celgene Corp. (NASDAQ:CELG) and Alexandria Venture Investments also participated. ...